The acquisition is stock-for-IP, and the terms are clean enough on paper. The seller is not an arm's-length party. Parkview Consulting LLC agreed on August 18, 2026 to transfer certain software, technology, domain names, and related intellectual property to Silo Pharma, Inc. (Nasdaq: SILO). Parkview's sole member and manager, Corwin Yu, simultaneously holds the title of lead strategic advisor on Silo's Cryptocurrency Advisory Board.
Silo paid no cash. The company issued 165,000 shares of common stock, par value $0.0001 per share, to Parkview as the entire consideration. Those shares are unregistered, offered and sold under Section 4(a)(2) of the Securities Act of 1933, a private-placement exemption that bypasses registration. A 12-month lock-up runs from the agreement's effective date of August 18. Parkview cannot sell, pledge, hedge, or otherwise transfer the shares during that window without Silo's prior written consent. Two carve-outs can end the lock-up early: a Change in Control as defined in the agreement, or written consent from the company.
The related-party structure is the read-through that matters. Yu holds no shares in the deal directly; Parkview, the LLC he controls, does. The filing does not describe what the software does, name the domains, or assign any valuation to the purchased assets. Schedules to the asset purchase agreement were omitted from the 8-K pursuant to Item 601(b)(10) of Regulation S-K, meaning the specifics are not yet in the public record.
The counterargument runs like this: related-party IP acquisitions with lock-ups and indemnification provisions are standard practice for small public companies. The agreement requires Parkview to indemnify Silo against misrepresentation, third-party intellectual property infringement, and acts of gross negligence, fraud, or intentional misconduct. The lock-up contains real teeth. Absent a Change in Control or written consent, Parkview holds a 12-month position it cannot exit.
On balance, the legal structure is conventional. What is not conventional is the combination. A pharma company with a Cryptocurrency Advisory Board acquiring software IP from that board's lead advisor, in an all-stock deal with no disclosed valuation, is a sentence worth parsing slowly. CEO Eric Weisblum signed the filing on August 19, 2026.